# MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

> **NCT01352273** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 69 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** MEK162 + RAF265

## Key facts

- **NCT ID:** NCT01352273
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352273, "MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01352273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*